Clinical evaluation of ceftazidime in internal medicine in Japan

A total of 424 medical patients were treated with ceftazidime: 376 were assessable for clinical efficacy and 413 for possible adverse events. The overall clinical efficacy rate was 80%. The eradication rates of initial pathogens were 82% in monomicrobial infections and 71% in polymicrobial infections. Adverse events considered to be attributable to ceftazidime were observed in 15 (3.6%) of the patients. Drug-related changes in laboratory parameters occurred in 29 patients but were always mild and transient. Ceftazidime appears to be a safe, efficacious antibiotic for treatment of infections in internal medicine.